论文部分内容阅读
目的:研究布地奈德气雾剂吸入治疗对支气管哮喘患儿外周血神经生长因子(NGF)水平的影响。方法:选择门诊支气管哮喘患儿52例分为两组,所有病例均在发作缓解期检测外周血神经生长因子及肺功能(FEV1),研究组36例为布地奈德气雾剂吸入治疗组,按06版GINA方案给予布地奈德气雾剂分级吸入预防治疗,对照组16例根据自愿原则未进行布地奈德气雾剂吸入治疗,3个月后再次检测所有患儿外周血神经生长因子水平及肺功能。结果:研究开始前两组患儿血清神经生长因子水平分别为(85.8±21.2)pg/ml和(66.4±15.6)pg/ml,3个月后布地奈德气雾剂吸入治疗组患儿血清神经生长因子浓度降为(45.6±12.2)pg/ml,与研究前差异具有统计学意义(P<0.001),同时FEV1明显提高(P<0.001),而未吸入激素治疗的患儿血清神经生长因子水平为(68.9±14.2)pg/ml,与研究开始前差异无统计学意义(P>0.05),FEV1未显示明显提高(P>0.05)。结论:布地奈德气雾剂吸入治疗能降低支气管哮喘患儿外周血神经生长因子水平。
OBJECTIVE: To study the effect of budesonide aerosol inhalation on peripheral nerve growth factor (NGF) levels in children with bronchial asthma. Methods: Fifty-two outpatients with bronchial asthma were selected and divided into two groups. All the patients were tested for peripheral nerve growth factor (NGF) and pulmonary function (FEV1) during the remission period. 36 patients in the study group were budesonide inhalation treatment group, According to the 06 version of GINA program budesonide aerosol grading inhalation prevention and treatment, the control group of 16 patients under the principle of voluntary budesonide aerosol inhalation treatment, 3 months after re-testing of all children with peripheral nerve growth factor levels And lung function. Results: Serum levels of NGF in the two groups before the study were (85.8 ± 21.2) pg / ml and (66.4 ± 15.6) pg / ml respectively. After 3 months, serum levels of budesonide inhalation The concentration of NGF was reduced to (45.6 ± 12.2) pg / ml, which was significantly different from that before the study (P <0.001) and significantly higher than that of FEV1 (P <0.001) (68.9 ± 14.2) pg / ml. There was no significant difference between the two groups (P> 0.05) and FEV1 (P> 0.05). Conclusions: Inhaled budesonide aerosol can reduce peripheral blood NGF in children with bronchial asthma.